Suppr超能文献

多原发性肿瘤能否作为胰腺癌患者p16INK4a种系突变的一个指标?

Multiple primary tumors as an indicator for p16INK4a germline mutations in pancreatic cancer patients?

作者信息

Gerdes B, Bartsch D K, Ramaswamy A, Kersting M, Wild A, Schuermann M, Frey M, Rothmund M

机构信息

Department of General Surgery, Philipps University of Marburg, Germany.

出版信息

Pancreas. 2000 Nov;21(4):369-75. doi: 10.1097/00006676-200011000-00007.

Abstract

Multiple primary tumors in pancreatic cancer patients might indicate a genetic predisposition to the development of malignancies. In this study we evaluated whether the mutation rate of the TP53 and p16INK4a genes of pancreatic cancers differs in pancreatic cancer patients with and without multiple primaries. Furthermore, we investigated whether pancreatic cancer patients with multiple primaries carry germline mutations in either p16INK4a, TP53, or BRCA2 tumor suppressor genes to detect a genetic alteration that predisposes to the development of different primaries. Fourteen (23%) of 60 pancreatic cancer patients developed histologically verified additional primaries during their lifetimes. Normal constitutional and tumor DNA of the 14 patients with a positive cancer history, but negative family history, were analyzed for p16INK4a, TP53, and BRCA2 mutations by single-strand conformational variant (SSCV) analysis and direct sequencing. Hypermethylation of the p16INK4a promoter region in pancreatic cancers was identified by methylation-specific polymerase chain reaction (PCR; MSP). Four of 14 pancreatic carcinomas carried somatic intragenic p16INK4a mutations, and another four tumors revealed hypermethylation of the p16INK4a promoter region. Somatic intragenic TP53 mutations were identified in six of 14 tumors. None of the pancreatic cancer patients carried TP53 or BRCA2 germline mutations. In contrast, one of 14 pancreatic cancer patients with multiple primaries carried the p16INK4a mutation A68V in his germline. This mutation was localized in the conserved second ankyrin repeat of p16INK4a and did not occur in 100 control patients. The frequency of somatic TP53 and p16INK4a mutations in pancreatic cancer is similar in patients with and without multiple primaries. TP53 and BRCA2 germline mutations seem not to be significantly associated with the occurrence of multiple primaries in pancreatic cancer patients. However, p16INK4a germline mutations might be causative for tumor development in some pancreatic cancer patients with multiple primaries. The genetic investigation of patients with accumulation of different cancers even without a positive family history may be a new approach for the understanding of the relation of different cancers.

摘要

胰腺癌患者出现多个原发性肿瘤可能提示存在发生恶性肿瘤的遗传倾向。在本研究中,我们评估了伴有或不伴有多个原发性肿瘤的胰腺癌患者中,胰腺癌TP53和p16INK4a基因的突变率是否存在差异。此外,我们调查了伴有多个原发性肿瘤的胰腺癌患者在p16INK4a、TP53或BRCA2肿瘤抑制基因中是否携带种系突变,以检测出一种导致不同原发性肿瘤发生的基因改变。60例胰腺癌患者中有14例(23%)在其一生中出现了经组织学证实的额外原发性肿瘤。对14例癌症病史阳性但家族史阴性患者的正常体质DNA和肿瘤DNA进行单链构象变异(SSCV)分析和直接测序,以检测p16INK4a、TP53和BRCA2基因突变。通过甲基化特异性聚合酶链反应(PCR;MSP)鉴定胰腺癌中p16INK4a启动子区域的高甲基化。14例胰腺癌中有4例携带p16INK4a基因内体细胞突变,另外4例肿瘤显示p16INK4a启动子区域高甲基化。14例肿瘤中有6例鉴定出体细胞TP53基因内突变。所有胰腺癌患者均未携带TP53或BRCA2种系突变。相比之下,14例伴有多个原发性肿瘤的胰腺癌患者中有1例其种系携带p16INK4a突变A68V。该突变位于p16INK4a保守的第二个锚蛋白重复序列中,在100例对照患者中未出现。伴有或不伴有多个原发性肿瘤的胰腺癌患者中,体细胞TP53和p16INK4a突变的频率相似。TP53和BRCA2种系突变似乎与胰腺癌患者多个原发性肿瘤的发生无显著关联。然而,p16INK4a种系突变可能是一些伴有多个原发性肿瘤胰腺癌患者肿瘤发生的原因。对即使没有阳性家族史但出现不同癌症聚集的患者进行基因研究,可能是理解不同癌症之间关系的一种新方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验